ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2026)

ARS Pharmaceuticals has disclosed Change in Acquisitions & Divestments across 4 years of filings, most recently posting $42.5 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $42.5 million, down 33.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $286.0 million (up 7.32% YoY), and the FY2025 annual result was $307.0 million, up 18.99% from the prior year.
• Change in Acquisitions & Divestments came in at $42.5 million for Q1 2026 at ARS Pharmaceuticals, down from $75.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $88.5 million in Q3 2025 to a low of $20.0 million in Q1 2023.
• The 4-year median for Change in Acquisitions & Divestments is $61.0 million (2024), against an average of $61.0 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 175.0% in 2024 and tumbled 33.07% in 2026, its largest moves.
• ARS Pharmaceuticals' Change in Acquisitions & Divestments stood at $60.0 million in 2023, then increased by 11.67% to $67.0 million in 2024, then gained by 11.94% to $75.0 million in 2025, then plunged by 43.33% to $42.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $42.5 million (Q1 2026), $75.0 million (Q4 2025), and $88.5 million (Q3 2025), per Business Quant data.